CD274 and non-small cell lung carcinoma: Both clinical factors associated with higher probability of response to nintedanib plus docetaxel (e.g. early progression or resistance to first-line therapy, high disease burden) or lower probability of response to nivolumab (e.g. ≥ 5 sites with lesions, bone or hepatic metastases, non-smoker status) and molecular criteria (PD-L1 expression) should be considered in deciding the optimal therapeutic approach for patients with pretreated NSCLC without actionable mutations.